Clinical trial services for multi-site Phase 3 studies have evolved far beyond the traditional “build or buy” decision — and the hybrid insourced CRO model is leading that shift.
Clinical trial services for multi-site Phase 3 studies have evolved far beyond the traditional “build or buy” decision — and the hybrid insourced CRO model is leading that shift. For pharmaceutical sponsors and CRO clinical operations leaders, the question today is not whether to outsource. It’s how much control to retain while still accessing the scale, site networks, and operational infrastructure that clinical trial management requires at the Phase 3 level.
What you’ll learn
- What defines hybrid clinical trial services — and how they differ from FSP and full-service
- The four criteria where they outperform: oversight, data quality, startup speed, and flexibility
- When hybrid clinical trial services are the right fit — and when they aren’t
- How to structure governance so the model doesn’t collapse under its own complexity
Clinical trial services: the problem with full outsourcing
Full-service CRO partnerships were designed for a world where sponsors lacked internal operational infrastructure. That world has changed. Most mid-to-large pharmaceutical sponsors today have clinical operations teams, established site relationships, and proprietary data standards — and many have experienced firsthand the friction that comes with handing an entire Phase 3 program to a single CRO.
The common complaints across clinical trial services engagements are consistent: startup timelines stretch to 14–18 months, site selection doesn’t reflect the sponsor’s therapeutic relationships, and data review cycles slow down because the CRO is managing queries at arm’s length. Sponsors lose visibility at the exact moment they need it most. “We had all the accountability and none of the control.” — a pattern clinical ops leaders describe when evaluating full-service CRO outcomes in multi-site Phase 3 programs.
What the hybrid clinical trial service model actually means
The hybrid or insourced CRO model is not a single structure — it’s a governance philosophy. The sponsor retains strategic and scientific ownership of the program. The CRO provides bandwidth, infrastructure, and specific execution capabilities within the sponsor’s clinical trial management framework. According to FDA guidance on clinical studies, sponsor oversight is a core regulatory expectation — and the hybrid model is designed specifically to preserve it.
In practice, hybrid clinical trial services can look like:
Embedded CRA teams
CRAs sourced from the CRO but managed by the sponsor’s clinical team, following sponsor SOPs
Sponsor-owned data
EDC and CTMS remain under sponsor control; the CRO executes within that environment
Shared site network
Sponsor’s preferred investigator sites augmented by the CRO’s network where capacity gaps exist
Function-by-function scope
Data management may stay in-house while monitoring is outsourced — each function defined separately
Where hybrid clinical trial services win in Phase 3
Oversight
You keep the steering wheel
Sponsor-led governance means protocol deviations, site performance issues, and data quality decisions come back to your team before they escalate. For Phase 3 programs heading toward regulatory submission, this level of control over clinical trial services is non-negotiable for most sponsors.
Data quality
Consistent standards across all sites
Because data systems stay under sponsor control and CRA staff operate under sponsor SOPs, data quality standards are uniform across all sites. This is where hybrid clinical trial management consistently outperforms full-service models. Compliance with ICH E6 Good Clinical Practice guidelines is easier to maintain when the sponsor owns the quality framework.
Startup speed
Faster than full-service, more scalable than in-house
Startup timelines improve because site selection doesn’t go through a CRO’s internal feasibility process. Sponsors use their existing site relationships and fill gaps with the CRO’s network. Typical activation for hybrid clinical trial services programs runs 20–35% faster than equivalent full-service engagements. See how FOMAT approaches clinical trial startup and site identification to understand the difference in practice.
Flexibility
Scope adjusts as the program evolves
Phase 3 programs change — amendments, enrollment challenges, regional expansion. Hybrid clinical trial management allows sponsors to shift scope in or out without renegotiating a full master service agreement.
When hybrid clinical trial services aren’t the right fit
Hybrid clinical trial services have a prerequisite: the sponsor must have at least a functional clinical operations core. This model does not work for early-stage companies running their first Phase 3 with no internal clinical infrastructure. In those cases, the coordination overhead will overwhelm a lean team faster than the alternative.
It is also not the best choice when speed to site activation is the single overriding priority — in that scenario, an SMO-led or full-service clinical trial service model will outperform. FOMAT’s Phase II–III clinical trial services cover both models depending on the sponsor’s needs and geography.
Hybrid model readiness checklist
- You have at least one experienced clinical program manager or VP Clinical Ops in-house
- You own your EDC and CTMS systems, or have vendor agreements where you control the data
- You have existing site relationships in at least the primary enrollment regions
- Your SOPs are documented and transferable to embedded CRO staff
- You’re willing to lead governance, not delegate it
4–5 checked: hybrid clinical trial services are likely the right fit. 2–3: consider FSP for a single function first. 1 or fewer: start with full-service and build internal capability in parallel.
Governance: the make-or-break factor in hybrid clinical trial management
The most common reason hybrid clinical trial services arrangements fail is not operational — it’s governance. When decision rights are split without a clear escalation path, ambiguity accumulates until a protocol deviation or enrollment shortfall forces a crisis conversation.
Three elements that make hybrid clinical trial management work:
1. A single sponsor decision authority
One named person on the sponsor side has final authority over scope, site, and data decisions. The CRO counterpart escalates to this person — not to a committee.
2. Function-level RACI documented upfront
Every clinical trial management function is assigned a clear owner before the program starts. Ambiguity in the RACI is a reliable predictor of future gaps in trial operations.
3. Weekly joint operational reviews
Not monthly — weekly. Site performance, enrollment velocity, and query resolution are reviewed jointly. Not reported from CRO to sponsor, but solved together.
The bottom line for clinical operations leaders
The hybrid insourced model represents the convergence of two pressures that have been building across clinical trial services for years: sponsors wanting more control over their Phase 3 programs, and CROs needing to offer more flexible, modular structures to retain clients who no longer need full outsourcing.
For multi-site Phase 3 programs where data quality and oversight matter as much as execution speed, hybrid clinical trial services offer the most balanced model available. The key is not finding the right CRO partner — it is designing the governance structure before the program starts, and committing to leading it rather than delegating it.
Comparing all 7 models? This article focuses on hybrid clinical trial services. For a full comparison of all seven clinical trial service models — including full-service CRO, FSP, SMO, DCT, in-house, and academic consortia — see the complete guide: 7 Clinical Trial Service Models for Phase 3 Studies.
Work with FOMAT
Ready to discuss which clinical trial service model fits your Phase 3 program? Our team works with sponsors and CROs across the US.